TSE:4528Pharmaceuticals
Assessing Ono Pharmaceutical (TSE:4528) Valuation After Ripretinib Approval Filing In Japan
Ripretinib filing puts Ono Pharmaceutical in focus
Ono Pharmaceutical (TSE:4528) has drawn fresh attention after applying in Japan for manufacturing and marketing approval of ripretinib for advanced gastrointestinal stromal tumor following prior cancer chemotherapy.
The filing is based on Phase 3 INVICTUS data, in which ripretinib extended progression free survival compared with placebo in heavily pretreated GIST patients. It follows approvals in more than 40 markets, including the U.S. and...